Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

• Status: Enrolling by invitation
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Frederick Health
• Treatments: Heparin

Criteria

Inclusion Criteria:

• Age ≥18 years

• Admitted to the intensive care unit

• Positive COVID-19 PCR

• Mechanical Ventilation for ≤ 48 hours

• PaO2/FiO2 ≤300

Exclusion Criteria:

• Heparin allergy

• Active bleeding

• Death or withdraw of care anticipated by intensivist within 24 hours

• Platelets< 50,000 cells/µL

• Clinically significant coagulopathy, as decided by the intensivist

• O2 dependent at baseline